Similar Posts
Industry NEWS: The GOOD, The BAD, And The UGLY / New Psychedelic Studies, Legalization Bills & MORE!
Hey guys! In this week’s general industry news, we’ll cover some interesting developments. Some are probably going to make some of our viewers turn away from this week’s episode as they discover some pretty “depressing” statistics about North America’s current mental state. However, for those who stick around, you might end up finding that there might be a light at the end of the tunnel as you discover that psilocybin’s benefits might be extended to treat certain
Enjoy!
Links:
Psilocybin & Migraines: https://www.psypost.org/2021/05/a-single-dose-of-psilocybin-has-a-lasting-therapeutic-effect-on-migraine-headache-according-to-a-new-placebo-controlled-study-60793Increased depression in North America:
https://www.meetfieldtrip.com/news/news-details/2021/Canadians-Are-Not-OK-83-of-Canadians-Report-One-Or-More-Symptoms-of-Depression-With-Many-Turning-To-Substances-To-Cope-With-Negative-Emotions-During-COVID-19-Pandemic-According-to-Field-Trip-Healths-First-Annual-State-of-Mind-Survey/default.aspxhttps://www.meetfieldtrip.com/news/news-details/2021/More-than-80-of-Americans-report-one-or-more-symptoms-of-depression-and-many-have-turned-to-substances-to-cope-with-negative-emotions-during-COVID-19-Pandemic-according-to-Field-Trip-Healths-First-Annual-State-of-Mind-Survey/default.aspx
Opioid Overdose In Ontario:
https://www.cp24.com/news/opioid-overdose-deaths-up-75-per-cent-in-ontario-during-covid-19-pandemic-new-report-1.5434080FDA Greenlights Ketamine:
https://psychedelicspotlight.com/ketamine-study-parkinsons-disease-treatment/California Bill to Decriminalize Psychedelics Passes Senate Floor:
https://www.marijuanamoment.net/california-bill-to-legalize-possession-of-psychedelics-heads-to-senate-floor-after-committee-action/Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
Follow us on social media! 🙌Instagram: @thepsychedelicinvestor
Email: thepsychedelicinvestor@gmail.com
Facebook: @thepsychedelicinvestor
Music: www.bensound.com
Video editing: @themyaholy
https://benzinga.grsm.io/jameshallifax1834
https://benzinga.grsm.io/thepsychedelicinvestorDISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.
#MindMed #PsychedelicStocks #PsychedelicIndustry
The Mainstream Media GETS Psychedelic Stocks [Like MMEDF, CMPS, EHVVF & FTRPF]
Hello psychedelic investors! Today’s episode will be a little different. We will discuss the recent media coverage of psychedelic stocks and its role in psychedelic inspired companies’ future.
It appears that the mainstream media understands the potential for psychedelic stocks to disrupt the pharmaceutical Industry. Now understanding what this means, and its implications is extremely important for retail investors like you and me.
We’ll also zoom into one piece of media about MindMed (MMED/MMEDF) and Compass Pathways (CMPS), and explore how it hits the nail on the head.
We are going to do this because one, it’s a good article that I wanted to share with you
And two, it exemplifies my point that the mainstream understands the potential here, and might actually be on the right side of history.P.S. I mention in the video that the article I’m discussing is by Yahoo Finance. It turns out the article is from OTC stock review.
For those interested in reading the entire article: https://ca.movies.yahoo.com/264-million-reasons-psychedelic-stocks-133000885.htmlTime Stamps
0:00 – Intro
3:10 – Media Coverage on Tesla & Psychedelic Stocks
6:36 – Benefits of the media covering Psychedelic Companies like (MMEDF & CMPS)
8:05 – Influence on stock valuations and stealth investors
10:57 – 264 Million Reasons Why Psychedelic Stocks Have More Room To GrowI hope you guys found some value in this and I’ll keep you posted for more changes!
Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
Follow us on social media! 🙌
Instagram: @psychedelicinvestorFacebook: @thepsychedelicinvestor
Music: www.bensound.comDISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
#MindMed #MindmedStock #PsychedelicStocks
Fireside Project – Destigmatizing Psychedelics as Healing Agents Through Risk Reduction
In this interview, Psychedelic Spotlight’s Swati Sharma and Fireside Co-Founder…
BIG MindMed MDMA Trial, Atai to Compete with Elon’s Neuralink ? (+ Updates on CMPS, MYCO and ENBI)
Hey Psychedelic Investors! There’s been so much news this week that we decided to split “This Week In Psychedelic Stocks” in 2 parts. Part Deux: ” BIG MindMed MDMA Trial, Atai’s to Compete with Tesla’s Neuralink (+Updates on CMPS, MYCO and ENBI)” might be a lot more interesting to some of you, however, I would suggest you watch Part I entitled: “HUGE Studies Released: Psychedelics About to TAKE OVER the Stock market?” That is if you are interested in the general developments in the psychedelic industry for this week.
In this episode, there’s lots of news for the psychedelic industry writ large. We’ll start up with three different studies that were released in the first week of April.
1. We’ll cover some MindMed News [ MMED / MMEDF recently announced a new MDMA study ]
2. Atai Life Sciences’ Computer Brain Interface & their clinical trial to treat Schizophrenia
3. Compass Pathways (CMPS) has amazing new price targets
4. Mydecine (MYCO / MYCOF ) has progressed four new compounds towards clinical trials
5. Entheon’s (ENBI / ENTBF) new Genetic Test Kit Updates…
Timestamps:
0:00 – Intro
1:47 – MindMed’s (MMED / MMEDF / MMQ) Announcing New Data on Personalized MDMA Dosing
6:08 – Atai Life Sciences acquires Psyber Inc to develop Brain Computer Interface -enabled digital therapeutics targeting mental health disorder
8:00 – Atai’s Subsidiary, Recognify Life Sciences, to Commence Phase 2 clinical study in Cognitive Impairment associated with Schizophrenia
9:07 – Roth Capital Upgrades Compass Pathways (CMPS) price targets & CMPS has scheduled a corporate update
10:32 – Mydecine ( MYCOF / MYCO ) Announces Four New Lead Drug Candidates for Pre-IND Meetings with the FDA & Health Canada to prepare for clinical trials. ( MYCO 001, MYCO 002, MYCO 003 & MYCO 004 )
13:02 – Entheon Biomedical (ENBI / ENTBF ) has now launched Halugen’s Psychedelics’ Genetic KIT
So that’s it for This Week in Psychedelic Stocks fellow psychedelic investors!I hope you guys found some value in this! As our thumbnail titles states: The SHROOM BOOM is REAL! Psychedelics are taking the world by storm and psychedelic inspired companies are releasing news every single day. We’ll try to cover most of them but if there’s a company you want us to cover more in debt, please let us know in the comments and we’ll try to satisfy your demands.
Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
Follow us on social media! 🙌
Instagram: @psychedelicinvestor
Facebook: @thepsychedelicinvestorIf you want to collaborate shoot us an email at: thepsychedelicinvestor@gmail.com
Music: www.bensound.com
https://benzinga.grsm.io/jameshallifa
…
https://benzinga.grsm.io/thepsychedelDISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
#MindMed #MMEDStock #CMPS Stock
Mixing Psychedelics & Antidepressants: Is it Safe? | NEW Psilocybin Study
As using psychedelics as medicines for mental health conditions has become more popular, it has been an open question of whether substances such as psilocybin (magic mushrooms) can safely be combined with anti-depressants such as SSRIs.
Now, Compass Pathways (CMPS) has released a small study, which showed that it is in fact safe to combine the two drugs. This is the second such small study to come to this conclusion. Earlier this year, MindMed, (MNMD / MMED) had released data on a similar study, with similar results
However, it is important to note that these are two very small studies, and that nothing has been definitively proven yet.
Many argue that psychedelics like psilocybin should be a replacement for depression medications such as SSRIs, not another layer of medicine. While I am sympathetic to this view, we must ultimately follow the science.
Compass Pathways will use the results of this trial to inform the design of their upcoming phase 3 trial testing whether psilocybin can treat treatment resistant depression.
Follow us on social media! 🙌
Instagram: @thepsychedelicinvestor
Facebook: @thepsychedelicinvestorWant to collaborate? Send us an email at:
thepsychedelicinvestor@gmail.comMusic from:
www.bensound.comVideo editing: @themyaholy
@Psychedelic Spotlight#psychedelics #antidepressants #psilocybin
Bad NEWS for NUMI, FieldTrip and J&J || Esketamine to Treat DEPRESSION Study Results And More
Hey Psychedelic Investors! There’s been so much news this week that we decided to split “This Week In Psychedelic Stocks” in 2 parts. Part Deux: ” BIG esketamine study results, new 5MEO-DMT tests and Updates on the decriminalization efforts in California and Texas.
In this episode, there’s lots of news for the psychedelic industry writ large. We’ll start up with three different studies that were released in the first week of April.
1. We’ll cover some interesting and maybe disappoint results coming from a study designed to determine whether esketamine can treat depression and their implications on some companies such as Numinus Wellness (NUMI), Field Trip Health ( FTRP) and Johnsons & Johnson (JNJ)
2. Study looking at the creativity benefits of taking psilocybin
3. Compass Pathways (CMPS) has amazing new price targets
4. First ever clinical trial testing the safety profile of a compound called 5MEO – DMT
5. A couple of updates on decriminalization effortsTimestapms:
0:00 – Intro
1:33 – Likelihood of Adverse events from Nasal Esketamine : Implications for Numinus, JNJ and Fieldtrip Health
6:07 – Psilocybin’s effects on creativity in a new placebo-controlled neuroimaging and it’s effects on MindMed (MMED/MMEDF), Compass Pathways (CMPS), Mydecine (MYCO) , Numinus ( NUMI)
11:25 – Researchers to team up to produce the first ever 5-meo-DMT Psychedelic Training Program
12:28 – California bill To Legalize Possession of Psychedelics Clears Second Senate Committee
14:26 – Rick Perry supports the Texas Capital to study psychedelic drugs from PTSD in veterans.I hope you guys found some value in this! As our thumbnail titles states: The SHROOM BOOM is REAL! Psychedelics are taking the world by storm and psychedelic inspired companies are releasing news every single day. We’ll try to cover most of them but if there’s a company you want us to cover more in debt, please let us know in the comments and we’ll try to satisfy your demands.
Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
Follow us on social media! 🙌
Instagram: @psychedelicinvestor
Facebook: @thepsychedelicinvestorIf you want to collaborate shoot us an email at: thepsychedelicinvestor@gmail.com
Music: www.bensound.com
https://benzinga.grsm.io/jameshallifa
…
https://benzinga.grsm.io/thepsychedelDISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.#PsychedelicStocks #Numi #Mindmed
![The Mainstream Media GETS Psychedelic Stocks [Like MMEDF, CMPS, EHVVF & FTRPF]](https://psychedelicspotlight.com/wp-content/uploads/2022/06/maxresdefault-43-600x338.jpeg)
